雅本化学(300261) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was approximately ¥530.44 million, representing a 12.80% increase compared to ¥470.24 million in the same period last year[13]. - Net profit attributable to shareholders decreased by 10.07% to approximately ¥50.97 million from ¥56.68 million year-on-year[13]. - The net profit after deducting non-recurring gains and losses was approximately ¥42.25 million, down 31.56% from ¥61.73 million in the previous year[13]. - Basic and diluted earnings per share were both ¥0.0532, down 9.52% from ¥0.0588 in the previous year[13]. - The weighted average return on equity was 2.45%, a decrease of 0.38% from 2.83% in the previous year[13]. - The company's operating income for the reporting period was 530.44 million yuan, an increase of 12.80% year-on-year, while the net profit attributable to shareholders was 50.97 million yuan, a decrease of 10.07% year-on-year[33]. - The total comprehensive income attributable to the parent company was ¥51,997,167.17, compared to ¥59,923,720.64 in the previous period, reflecting a decrease of about 13%[95]. Cash Flow and Financial Position - The net cash flow from operating activities was negative at approximately -¥17.18 million, a significant decline from ¥298.32 million in the same period last year, representing a decrease of 105.76%[13]. - The net cash flow from operating activities for the reporting period was a net outflow of 17.18 million yuan, a decrease of 105.76% compared to the net inflow of the same period last year, mainly due to a decrease in cash received from sales of goods and an increase in cash paid for purchases[29]. - The cash inflow from operating activities totaled ¥486,524,248.11, down from ¥684,719,240.65 in the previous period, indicating a decrease of approximately 29%[107]. - The ending cash and cash equivalents balance was 411,426,170.38, down from 511,098,075.45 in the previous period[109]. - The company reported a net increase in cash and cash equivalents of 53,842,175.16, compared to 43,266,802.71 in the previous period[113]. - The total cash outflow from investing activities was ¥112,289,675.97, up from ¥86,987,025.05 in the previous period, indicating an increase of about 29%[107]. Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥4.10 billion, an increase of 3.41% from ¥3.96 billion at the end of the previous year[13]. - The company's total assets increased to ¥2,690,439,752.58 from ¥2,484,689,584.78, marking a growth of 8.3%[85]. - The total liabilities of the company were CNY 1,878,147,432.45 as of March 31, 2021, compared to CNY 1,798,969,860.27 at the end of 2020, which is an increase of about 4.4%[75][78]. - Total liabilities increased to ¥931,690,155.93, up from ¥746,395,849.61, reflecting a growth of 24.8%[85]. - The company's equity attributable to shareholders reached CNY 2,102,930,420.56, up from CNY 2,050,933,253.39, representing a growth of approximately 2.5%[78]. Investments and Projects - The company has invested a total of ¥69.12 million in fundraising projects, with a cumulative investment of 86.50% in the Nantong base new production line project, expected to be completed by July 31, 2021[48]. - The company has achieved a 24.23% investment completion rate for the Binhai base new production line project, with an expected completion date of May 31, 2021[48]. - The Nantong base's new production line project has been delayed to July 2021 due to production suspension for rectification and safety inspections following the "3.21" chemical plant explosion[51]. - The Binhai base's new production line project has also been postponed to May 2021 due to similar safety and environmental regulations[51]. Market and Operational Strategy - The company is actively promoting the construction of a synthetic biology technology platform and the development of new products, with new health products gradually launched on overseas e-commerce platforms to meet diverse consumer health needs[33]. - The company plans to closely monitor changes in the macroeconomic environment and raw material prices to mitigate risks and ensure stable operations[37]. - The company is focusing on expanding its market presence for new biotechnology products developed through its synthetic biology platform, despite potential risks in market promotion and sales performance[38]. - The company has established a dedicated team for market research and competitive analysis to optimize marketing management for new product sales[38]. Shareholder and Corporate Governance - The company had a total of 35,757 common shareholders at the end of the reporting period[18]. - The company has committed to strict adherence to its promises regarding share transfer limits and management activities, ensuring no unfair benefits are provided to other parties[41]. - The company repurchased 8,623,900 shares, accounting for 0.90% of the total share capital, with a total transaction amount of approximately ¥34.98 million, at a price range of ¥3.82 to ¥4.26 per share[39].